scholarly article | Q13442814 |
P356 | DOI | 10.1158/1078-0432.CCR-07-0648 |
P698 | PubMed publication ID | 17975155 |
P50 | author | Robert L Vessella | Q106509691 |
Ilsa Coleman | Q114402120 | ||
P2093 | author name string | Stephen R Plymate | |
Peter Nelson | |||
Dale L Ludwig | |||
Kathy Haugk | |||
R Bruce Montgomery | |||
Jennifer D Wu | |||
Lillie Woodke | |||
P433 | issue | 21 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | prostate cancer | Q181257 |
preproinsulin | Q7240673 | ||
P304 | page(s) | 6429-6439 | |
P577 | publication date | 2007-11-01 | |
P1433 | published in | Clinical Cancer Research | Q332253 |
P1476 | title | An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer | |
P478 | volume | 13 |
Q34336988 | Can we unlock the potential of IGF-1R inhibition in cancer therapy? |
Q34712380 | Critical role of a survivin/TGF-β/mTORC1 axis in IGF-I-mediated growth of prostate epithelial cells |
Q39711107 | Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells |
Q37542952 | Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions |
Q37876194 | Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer |
Q37826274 | Future directions in castrate-resistant prostate cancer therapy. |
Q37381766 | Implications of insulin-like growth factor-I for prostate cancer therapies |
Q42837186 | Inhibition of the insulin-like growth factor-1 receptor enhances effects of simvastatin on prostate cancer cells in co-culture with bone |
Q42248557 | Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone |
Q29619495 | Insulin and insulin-like growth factor signalling in neoplasia |
Q38641329 | Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies |
Q38177688 | Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy |
Q34551541 | Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels |
Q35121509 | Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma is associated with increased autocrine of IGF1. |
Q33642278 | Novel targeted therapeutics for metastatic castration-resistant prostate cancer. |
Q35838821 | Oncogenic activation in prostate cancer progression and metastasis: Molecular insights and future challenges |
Q37519616 | Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer |
Q35603263 | Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation |
Q35563844 | SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer |
Q54650111 | Serial analysis of resected prostate cancer suggests up‐regulation of type 1 IGF receptor with disease progression |
Q37310963 | Serially heterotransplanted human prostate tumours as an experimental model |
Q37575815 | Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy |
Q37859024 | Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer |
Q39205279 | Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts |
Q37344395 | Targeting of the protein interaction site between FAK and IGF-1R. |
Q37304764 | The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer |
Q42951499 | Transforming Growth Factor-{beta}-Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition |
Search more.